-transparent.png){kind=logo}
We report on three observations of parkinsonian patients with levo-dopa-induced diphasic dyskinesias, who received subcutaneous apomorphine to reduce the duration of abnormal movements. Apomorphine was effective in reducing the duration of diphasic dyskinesias at doses higher than the threshold doses necessary to induce an "on" phase (mean increase: 43%). However, after a few months of treatment, apomorphine was ineffective in stopping abnormal movements, even when doses were increased. In two patients, apomorphine remained effective in the morning, but increased the intensity of the dyskinesias in the afternoon. Acute diurnal variations of the pharmacodynamic striatal response are suggested explanation for these clinical observations.
F Durif, and
D Deffond, and
G Dordain, and
M Tournilhac
March 1975,
Lancet (London, England),
F Durif, and
D Deffond, and
G Dordain, and
M Tournilhac
January 1992,
Movement disorders : official journal of the Movement Disorder Society,
F Durif, and
D Deffond, and
G Dordain, and
M Tournilhac
August 1982,
Archives of neurology,
F Durif, and
D Deffond, and
G Dordain, and
M Tournilhac
January 1982,
Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952),
F Durif, and
D Deffond, and
G Dordain, and
M Tournilhac
January 2021,
Movement disorders : official journal of the Movement Disorder Society,
F Durif, and
D Deffond, and
G Dordain, and
M Tournilhac
April 2008,
Clinical neurology and neurosurgery,
F Durif, and
D Deffond, and
G Dordain, and
M Tournilhac
August 2017,
Neurology,
F Durif, and
D Deffond, and
G Dordain, and
M Tournilhac
February 2013,
Movement disorders : official journal of the Movement Disorder Society,
F Durif, and
D Deffond, and
G Dordain, and
M Tournilhac
January 1986,
Psychopharmacology,
F Durif, and
D Deffond, and
G Dordain, and
M Tournilhac
January 2020,
NPJ Parkinson's disease,
